ArticleJBMR plus2025
Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study.
Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Biochemical bone biomarkers in plasma cell dyscrasias.British journal of haematology · 2026Review
- Management of bone metastases in patients with breast cancer: review of bone-modifying therapy, emerging new agents, and future directions.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone damage occurs early in the progression of plasma cell disorders. Romosozumab (ROMO), a sclerostin inhibitor with both anabolic and antiresorptive effects, may provide therapeutic benefit for this fracture-prone population. We conducted a 12-mo prospective observational study on postmenopausal women with osteoporosis and multiple myeloma (MM) treated with monthly ROMO. BMD was assessed at baseline, 6, and 12 mo with DXA and HR-pQCT. Additionally, bone turnover markers (BTMs) and several MM markers were also monitored. Eight female patients with MM without evidence of CRAB completed 12 mo of ROMO. A significant BMD increase was observed at the LS (+5.8%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.